Literature DB >> 18604233

Principles of safety pharmacology.

M K Pugsley1, S Authier, M J Curtis.   

Abstract

Safety Pharmacology is a rapidly developing discipline that uses the basic principles of pharmacology in a regulatory-driven process to generate data to inform risk/benefit assessment. The aim of Safety Pharmacology is to characterize the pharmacodynamic/pharmacokinetic (PK/PD) relationship of a drug's adverse effects using continuously evolving methodology. Unlike toxicology, Safety Pharmacology includes within its remit a regulatory requirement to predict the risk of rare lethal events. This gives Safety Pharmacology its unique character. The key issues for Safety Pharmacology are detection of an adverse effect liability, projection of the data into safety margin calculation and finally clinical safety monitoring. This article sets out to explain the drivers for Safety Pharmacology so that the wider pharmacology community is better placed to understand the discipline. It concludes with a summary of principles that may help inform future resolution of unmet needs (especially establishing model validation for accurate risk assessment). Subsequent articles in this issue of the journal address specific aspects of Safety Pharmacology to explore the issues of model choice, the burden of proof and to highlight areas of intensive activity (such as testing for drug-induced rare event liability, and the challenge of testing the safety of so-called biologics (antibodies, gene therapy and so on.).

Entities:  

Mesh:

Year:  2008        PMID: 18604233      PMCID: PMC2492105          DOI: 10.1038/bjp.2008.280

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  80 in total

1.  Torsades de pointes with terfenadine ingestion.

Authors:  R A June; I Nasr
Journal:  Am J Emerg Med       Date:  1997-09       Impact factor: 2.469

Review 2.  High throughput assay technologies for ion channel drug discovery.

Authors:  Wei Zheng; Robert H Spencer; Laszlo Kiss
Journal:  Assay Drug Dev Technol       Date:  2004-10       Impact factor: 1.738

3.  Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?

Authors:  C M Pratt; A J Camm; W Cooper; P L Friedman; D J MacNeil; K M Moulton; B Pitt; P J Schwartz; E P Veltri; A L Waldo
Journal:  Am J Cardiol       Date:  1998-04-01       Impact factor: 2.778

Review 4.  Of oocytes and runny noses.

Authors:  M R Rosen
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

5.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.

Authors:  M Roy; R Dumaine; A M Brown
Journal:  Circulation       Date:  1996-08-15       Impact factor: 29.690

6.  Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation.

Authors:  J N Weiss; A Garfinkel; H S Karagueuzian; Z Qu; P S Chen
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

Review 7.  Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias?

Authors:  S Rees; M J Curtis
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

Review 8.  Arrhythmogenic mechanisms of non-sedating antihistamines.

Authors:  Y G Yap; A J Camm
Journal:  Clin Exp Allergy       Date:  1999-07       Impact factor: 5.018

9.  An in vitro method for the evaluation of antiarrhythmic and antiischemic agents by using programmed electrical stimulation of rabbit heart.

Authors:  J Bellemin-Baurreau; A Poizot; P E Hicks; J M Armstrong
Journal:  J Pharmacol Toxicol Methods       Date:  1994-02       Impact factor: 1.950

Review 10.  Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation.

Authors:  M J Curtis
Journal:  Cardiovasc Res       Date:  1998-07       Impact factor: 10.787

View more
  36 in total

1.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Continuity and change.

Authors:  H P Rang; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 4.  The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.

Authors:  Borje Darpo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

5.  Mediators and receptors in the resolution of inflammation: drug targeting opportunities.

Authors:  A G Stewart
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

6.  Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs.

Authors:  Nathan M Appel; Shou-Hua Li; Tyson H Holmes; Jane B Acri
Journal:  J Pharmacol Exp Ther       Date:  2015-07-15       Impact factor: 4.030

Review 7.  Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery.

Authors:  Ali Nsair; W Robb MacLellan
Journal:  Adv Drug Deliv Rev       Date:  2011-03-01       Impact factor: 15.470

8.  Mass psychogenic illness following HPV immunization in Carmen de Bolivar, Colombia (2014): more uncertainty is required.

Authors:  Alvaro J Idrovo; Gabriel D Pinilla-Monsalve; Edgar F Manrique-Hernández
Journal:  Hum Vaccin Immunother       Date:  2019-04-02       Impact factor: 3.452

Review 9.  Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Authors:  Jean-Pierre Valentin; Chris Pollard; Pierre Lainée; Tim Hammond
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

10.  Effect of Wearing a Telemetry Jacket on Behavioral and Physiologic Parameters of Dogs in the Open-Field Test.

Authors:  Richard E Fish; Melanie L Foster; Margaret E Gruen; Barbara L Sherman; Davidc C Dorman
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-07-01       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.